


AMENDMENTS TO THE CLAIMS

Please cancel claim 27 without prejudice and amend claims 4-21, 23-25, 31-33, and 37-38 as shown below. A complete listing of the claims in this case, with their status, is shown below.

1. **(Original)** A compound of Formula I or a salt thereof,



wherein;

R₁ and R₂ are independently selected from the group consisting of: -CH₃, -CH₂CH₃, -CH₂OH, -CH₂OR', -CHO, -CO₂H, and -CO₂R';

R₃ and R₄ are independently selected from the group consisting of: H, -CH₃, -CH₂CH₃, -CH₂OH, -CH₂OR', -CHO, -CO₂H, and -CO₂R';






Q is a carbon skeleton selected from the group consisting of: -CH₂-, -CY₁Y₂-, -CH₂CH₂-, -CH=CH-, -CY₁Y₂CY₃Y₄-, -CH₂CH₂CH₂-, -CH=CHCH₂-, -CH=CHCY₁Y₂-, and -CY₁Y₂CY₃Y₄CY₅Y₆-; where Y₁, Y₂, Y₃, Y₄, Y₅, and Y₆ are independently selected from the group consisting of: H, F, Br, Cl, I, OH, OR', and SH; or any one group of Y₁/Y₂, Y₃/Y₄, and Y₅/Y₆ may be =O; or Y₁/Y₃ may form an epoxide; and, at least one of Y₁, Y₂, Y₃, Y₄, Y₅ and Y₆ when present, is not H;

X₁, X₂, X₃, and X₄ are independently selected from the group consisting of: H, R, OH, -OR, -CO₂H, -CO₂R', F, Br, Cl, I, -CN, -SO₃H, -OSO₃H, NO₂, NH₂, -NHR, and -NR₂; where R is a linear, branched, or cyclic, saturated or unsaturated one to ten carbon alkyl group that is unsubstituted or is substituted with one or more of: OH, =O, SH, F, Br, Cl, I, NH₂, -NHR', -NR'₂, NO₂, -CO₂H, -CO₂R', and epoxide;


and R' is a linear, branched, or cyclic, saturated or unsaturated one to ten carbon alkyl group that is unsubstituted or substituted with one or more of: OH, =O, SH, F, Br, Cl, I, NH₂, -NHR'',

-NR², NO₂ and -CO₂H where R² is a linear, branched, or cyclic, saturated or unsaturated one to ten carbon alkyl group;

providing that the compound does not have the precise structure of pelorol or any one of the group of structures consisting of:



and



2. (Original) The compound of claim 1, wherein $Y_1 - Y_6$ are independently selected from H, F, Br, Cl and I.
3. (Original) The compound of claim 1, wherein Q is $-CH_2-$, $-CH_2CH_2-$, $-CH=CH-$, $-CH_2-CH_2CH_2-$, or $-CH=CHCH_2-$.
4. (Amended) The compound of claim 1, ~~2, or 3~~, wherein the carbon skeleton of Q is saturated.
5. (Amended) The compound of claim 1 ~~any one of claims 1-4~~, wherein the carbon skeleton of Q consists of one or two carbon atoms.
6. (Amended) The compound of claim 1 ~~any one of claims 1-5~~, wherein R_1 is methyl, ethyl, $-CH_2OH$, or $-CH_2OR'$.
7. (Amended) The compound of claim 1 ~~any one of claims 1-6~~, wherein R_2 is methyl, ethyl, $-CH_2OH$, or $-CH_2OR'$.
8. (Amended) The compound of claim 1 ~~any one of claims 1-7~~, wherein R' in R_1 is limited to methyl, ethyl, propyl or butyl.
9. (Amended) The compound of claim 1 ~~any one of claims 1-8~~, wherein R' in R_2 is limited to methyl, ethyl, propyl or butyl.
10. (Amended) The compound of claim 8 ~~claim 8 or 9~~, wherein R' is limited to methyl or ethyl.
11. (Amended) The compound of claim 1 ~~any one of claims 1-10~~, wherein X_1 is H, OH, R, OR, $-CONH_2$, $-CONHR'$, or $-COR'_2$.

12. (Amended) The ~~compound~~ compound of claim 1 ~~any one of claims 1-11~~, wherein X₂ is H, OH, R, OR, -CONH₂, -CONHR', or -COR'₂.
13. (Amended) The compound of claim 1 ~~any one of claims 1-12~~, wherein X₃ is H, OH, R, OR, -CONH₂, -CONHR', or -COR'₂.
14. (Amended) The compound of claim 1 ~~any one of claims 1-13~~, wherein R and R' in one or more of X₁, X₂, and X₃ are limited to methyl, ethyl, propyl and butyl.
15. (Amended) The compound of claim 1 ~~any one of claims 1-10~~, wherein X₁ is H, OH, or -OCH₃.
16. (Amended) The compound of claim 1 ~~any one of claims 1-10 and 15~~, wherein X₂ is H, OH, or OCH₃.
17. (Amended) The compound of claim 1 ~~any one of claims 1-10 and 15~~, wherein X₂ is H, OCH₃, or -NH₂CH₃.
18. (Amended) The compound of claim 1 ~~any one of claims 1-10, 15, 16, and 17~~, wherein X₃ is H, OH, or OCH₃.
19. (Amended) The compound of claim 1 ~~any one of claims 1-18~~, wherein X₄ is H, R, OH, OR, CO₂H or CO₂R'.
20. (Amended) The compound of claim 1 ~~any one of claims 1-19~~, wherein R and R' in X₄ are limited to methyl, ethyl, propyl or butyl.
21. (Amended) The compound of claim 1 ~~any one of claims 1-18~~, wherein X₄ is H, R, OH, OCH₃, -CO₂H or -CO₂CH₃.

22. **(Original)** The compound of claim 1, selected from: homopelolorol, dimethoxypelolorol, PNSR-4A, PNSR-15A, PNSR-16A, PNSR-17A and PNSR-18A.

23. **(Amended)** The compound of claim 1 ~~any one of claims 1-22~~, having the configuration S, R, R, S at C-5, C-8, C-9 and C-10 respectively.


24. **(Amended)** The compound of claim 1 ~~any one of claims 1-22~~, having the configuration R, S, S, R at C-5, C-8, C-9 and C-10 respectively.

25. **(Amended)** The compound of claim 1 ~~any one of claims 1-24~~, for use as a modulator of SHIP 1 activity.


26. **(Original)** The compound of claim 25, wherein the compound is an agonist of SHIP 1 activity.

27. **(Canceled)**


28. **(Original)** A method of making a compound of Formula IA in which $R_1 - R_4$, X_1 , X_3 and X_4 are as defined in claim 1,




wherein, L' is a $C_1 - C_4$ saturated or unsaturated alkyl linking group; and A is an activating group; comprising reacting a compound of Formula IIA or IIB:



in which L is absent or is a C₁ – C₃ saturated or unsaturated alkyl linking group and E and E' are electrophilic reactive groups; with a compound of Formula III





in which Nu is a group that renders the compound of Formula III nucleophilic at Nu, followed by optional reduction and by hydrolysis, to produce a compound of Formula IV





and condensing the compound of Formula IV to produce a compound of Formula IA.

29. (Original) The method of claim 28, wherein the compounds of Formula IIA and IIB have the structures:



30. (Original) The method of claim 29, wherein the compounds of Formula IIA and IIB have the structures




31. (Amended) The method of claim 28 ~~any one of claims 28-30~~, wherein the compound of Formula IIA or IIB is sclareolide or is derived from sclareolide.

32. (Amended) The method of claim 28 ~~any one of claims 28-31~~, wherein Nu is lithium.

33. (Amended) The method of claim 28 ~~any one of claims 28-32~~, wherein A is OCH₃ or –NHCH₃.

34. (Original) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and one or more compounds of Formula I or pharmaceutically acceptable salts thereof,



wherein;

R₁ and R₂ are independently selected from the group consisting of: -CH₃, -CH₂CH₃, -CH₂OH, -CH₂OR', -CHO, -CO₂H, and -CO₂R';

R₃ and R₄ are independently selected from the group consisting of: H, -CH₃, -CH₂CH₃, -CH₂OH, -CH₂OR', -CHO, -CO₂H, and -CO₂R';

Q is a carbon skeleton selected from the group consisting of: -CH₂-, -CY₁Y₂-, -CH₂CH₂-, -CH=CH-, -CY₁Y₂CY₃Y₄-, -CH₂CH₂CH₂-, -CH=CHCH₂-, -CH=CHCY₁Y₂-, and -CY₁Y₂CY₃Y₄CY₅Y₆-; where Y₁, Y₂, Y₃, Y₄, Y₅, and Y₆ are independently selected from the group consisting of: H, F, Br, Cl, I, OH, OR', and SH; or any one group of Y₁/Y₂, Y₃/Y₄, and Y₅/Y₆ may be =O; or Y₁/Y₃ may form an epoxide; and, at least one of Y₁, Y₂, Y₃, Y₄, Y₅ and Y₆ when present, is not H;

X₁, X₂, X₃, and X₄ are independently selected from the group consisting of: H, R, OH, -OR, -CO₂H, -CO₂R', F, Br, Cl, I, -CN, -SO₃H, -OSO₃H, NO₂, NH₂, -NHR, and -NR₂; where R is a linear, branched, or cyclic, saturated or unsaturated one to ten carbon alkyl group that is unsubstituted or is substituted with one or more of: OH, =O, SH, F, Br, Cl, I, NH₂, -NHR', -NR'₂, NO₂, -CO₂H, -CO₂R', and epoxide;

and R' is a linear, branched, or cyclic, saturated or unsaturated one to ten carbon alkyl group that is unsubstituted or substituted with one or more of: OH, =O, SH, F, Br, Cl, I, NH₂, -NHR'', -NR''₂, NO₂ and -CO₂H where R'' is a linear, branched, or cyclic, saturated or unsaturated one to ten carbon alkyl group.

35. **(Original)** The pharmaceutical composition of claim 34, wherein the one or more compounds of Formula I is not solely pelorol.

36. **(Original)** The pharmaceutical composition of claim 34, comprising pelorol.

37. **(Amended)** The pharmaceutical composition of claim 34, ~~35, or 36,~~ comprising a compound according to **claim 1** ~~any one of claims 1-26.~~

38. **(Amended)** A method of prophylaxis or treatment of an immune, hematopoietic, inflammatory or neoplastic disorder or condition comprising administering to a patient in need of said prophylaxis or treatment, an effective amount of a pharmaceutical composition according to **claim 34.** ~~any one of claims 34-37.~~